Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec;36(12):2455-2456.
doi: 10.1002/jbmr.4317. Epub 2021 May 24.

Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing

Suzanne M Jan de Beur  1 , Paul D Miller  2 , Thomas J Weber  3 , Munro Peacock  4 , Karl Insogna  5 , Rajiv Kumar  6 , Frank Rauch  7 , Diana Luca  8 , Tricia Cimms  8 , Mary Scott Roberts  8 , Javier San Martin  8 , Thomas O Carpenter  5
Affiliations
Comment

Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing

Suzanne M Jan de Beur et al. J Bone Miner Res. 2021 Dec.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Jan de Beur SM, Miller PD, Weber TJ, et al. Burosumab for the treatment of tumor‐induced osteomalacia. J Bone Miner Res. 2021;36(4):627‐635. - PMC - PubMed
    1. Insogna KL, Briot K, Imel EA, et al. A randomized, double‐blind, placebo‐controlled, phase 3 trial evaluating the efficacy of burosumab, an anti‐FGF23 antibody, in adults with X‐linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383‐1393. - PubMed
    1. Insogna KL, Rauch F, Kamenický P, et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X‐linked hypophosphatemia: a phase 3, single‐arm, international trial. J Bone Miner Res. 2019;34(12):2183‐2191. - PMC - PubMed
    1. Portale AP, Carpenter TO, Brandi ML, et al. Continued beneficial effects of burosumab in adults with X‐linked hypophosphatemia: results from a 24‐week treatment continuation period after a 24‐week double‐blind placebo‐controlled period. Calcif Tissue Int. 2019;105(3):271‐284. - PubMed
    1. Matin P. The appearance of bone scans following fractures, including immediate and long‐term studies. J Nucl Med. 1979;20(12):1227‐1231. - PubMed

Substances

Supplementary concepts